AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27139495
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (CSI) - one ultrasound guided injection around the affected tendons and advice on tendon care.
Trial: 27139495
Drug: Physiotherapist-administered load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapist-administered load modification and exercise intervention - education about load modification and a home-based and supervised exercise programme.
Trial: 24887686
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/d for 1 week)
Trial: 24887686
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/d for 1 week) with meloxicam
Trial: 7487212
Drug: 80 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 micrograms/kg body weight recombinant human insulin-like growth factor-I (rhlGF-I)
Trial: 2225606
Drug: Prostaglandin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin treatment (self-administered or given at the clinic)
Trial: 2225606
Drug: Self-administered prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered prostaglandin treatment
Trial: 31030606
Drug: Perindopril-indapamide treatment
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril-indapamide treatment
Trial: 25104617
Drug: Pemetrexed maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed maintenance (500 mg/m², day 1) plus best supportive care (BSC)
Trial: 20637958
Drug: FDC ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FDC ibuprofen 400 mg/paracetamol 1000 mg
Trial: 20637958
Drug: FDC ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FDC ibuprofen 200 mg/paracetamol 500 mg
Trial: 20637958
Drug: All FDC
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All FDC treatments
Trial: 20637958
Drug: Ibuprofen 100
RxNorm normalized name: ibuprofen 100 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 100 mg/paracetamol 250 mg
Trial: 20637958
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg/paracetamol 500 mg
Trial: 20637958
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/paracetamol 1000 mg
Trial: 10963021
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (SLT) involvement
Trial: 8886552
Drug: Radio-opaque markers
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio-opaque markers (ROMs) with a test meal (451 kcal) containing a capsule with 10 ROMs, assessed after 6 hours
Trial: 8886552
Drug: MRI study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MRI study with 500 ml intralipid 10% (550 kcal)
Trial: 6424492
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) 20 mg, thrice daily for 3 weeks
Trial: 31987407
Drug: Palbociclib at
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years with endocrine therapy
Trial: 21862455
Drug: Angiotensin Receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin Receptor Blockade (ARB; losartan 100 mg/day)
Trial: 21862455
Drug: ARB +
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB + Diuretics (losartan 100 mg/day plus hydrochlorothiazide 25 mg/day)
Trial: 21862455
Drug: LS and
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LS and Diuretics
Trial: 19291085
Drug: Daunorubicin 50
RxNorm normalized name: DAUNOrubicin 50 MG in 10 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin 50 mg/m(2)
Trial: 19291085
Drug: Daunorubicin 35
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin 35 mg/m(2)
Trial: 19291085
Drug: Cytarabine 200
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 200 mg/m(2)
Trial: 19291085
Drug: Cytarabine 400
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 400 mg/m(2)
Trial: 19291085
Drug: PSC‐833 (multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSC‐833 (multidrug resistance modulator)
Trial: 19291085
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of treatment
Trial: 17975181
Drug: Risperidone 1
RxNorm normalized name: risperidone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1 mg/d (increased to 2 mg/d after 4 weeks if needed)
Trial: 9689829
Drug: T4 replacement
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 replacement therapy in Group A (Congenital Hypothyroidism)
Trial: 9689829
Drug: Long-term T4
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term T4 replacement therapy
Trial: 8106768
Drug: Teicoplanin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (6 mg/kg every 24 h i.v. after initial loading every 12 h for three doses)
Trial: 8106768
Drug: Vancomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (15 mg/kg every 12 h i.v.)
Trial: 2566337
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg almitrine bismesylate
Trial: 2566337
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg almitrine bismesylate
Trial: 2566337
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg almitrine bismesylate
Trial: 2566337
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg almitrine bismesylate
Trial: 28802552
Drug: Mushroom-retained gastrostomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mushroom-retained gastrostomy (MG)
Trial: 22028630
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup C conjugate vaccine in 10 control villages
Trial: 12584834
Drug: Composite Salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Salvia Injection (CSI)
Trial: 10511060
Drug: Clenoliximab (IDEC‐151),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenoliximab (IDEC‐151), a chimeric monoclonal antibody, administered as a single intravenous infusion.
Trial: 8555987
Drug: Almitrine 50
RxNorm normalized name: almitrine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 50 mg twice a day by mouth for 60 days
Trial: 1785379
Drug: Neoadjuvant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant cyclophosphamide + doxorubicin + cisplatin (CAP) plus radiation therapy
Trial: 1785379
Drug: Neoadjuvant methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant methotrexate + vinblastine + doxorubicin + cisplatin (M‐VAC) therapy
Trial: 7059418
Drug: Hydrochlorothiazide plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide plus acebutolol (up to 800 mg daily)
Trial: 7059418
Drug: Acebutolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (up to 2000 mg daily)
Trial: 20819550
Drug: 0.3% gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% gatifloxacin ophthalmic gel
Trial: 20819550
Drug: 0.3% gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% gatifloxacin ophthalmic solution
Trial: 25057270
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 (240 mg per day)
Trial: 25057270
Drug: Betahistine (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (32 mg per day)
Trial: 21138337
Drug: Tobramycin/dexamethasone ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% (TobraDex ST) dosed 1 drop QID for 14 days
Trial: 21138337
Drug: Azithromycin ophthalmic
RxNorm normalized name: azithromycin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin ophthalmic solution 1% dosed 1 drop BID for 2 days followed by QD for 12 days
Trial: 22435514
Drug: Artichoke juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke juice concentrate (50 mg)
Trial: 22435514
Drug: Artichoke juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke juice concentrate (100 mg)
Trial: 17570960
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy through Internet chat (12-15 weeks, 90 min weekly)
Trial: 17894051
Drug: L-Tryptophan treatment
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Tryptophan treatment
Trial: 17894051
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment with L-Tryptophan)
Trial: 31733631
Drug: LSD (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (0.1 mg)
Trial: 31733631
Drug: d-amphetamine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (40 mg)
Trial: 30653847
Drug: Liraglutide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.3 mg starting dose, escalating to 3.0 mg or maximum tolerated dose)
Trial: 26320489
Drug: Dose-dense cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense cisplatin plus fluorouracil following selective radiotherapy
Trial: 26320489
Drug: Dose-dense cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense cisplatin plus fluorouracil following selective radiotherapy (subgroup analysis)
Trial: 23585663
Drug: VRS-317 (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRS-317 (0.05, 0.10, 0.20, 0.40, and 0.80 mg/kg)
Trial: 23585663
Drug: VRS-317 (0.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRS-317 (0.80 mg/kg)
Trial: 11010838
Drug: cpts-248/404 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cpts-248/404 vaccine
Trial: 26630719
Drug: Ketoprofen 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 37.5 mg
Trial: 26630719
Drug: Ketoprofen 12.5
RxNorm normalized name: ketoprofen 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 12.5 mg and Ketoprofen 37.5 mg
Trial: 28528211
Drug: Intravenous Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Levetiracetam (LEV)
Trial: 28528211
Drug: Intravenous Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Phenytoin (DPH)
Trial: 21974796
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (50 mg.kg(‐1) in 100 ml saline over 10 min followed by a continuous infusion of 20 mg.kg.h(‐1))
Trial: 11966500
Drug: Sodium monofluorophosphate
RxNorm normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium monofluorophosphate (150 mg) with calcium (1 g) and vitamin D (800 IU)
Trial: 11966500
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g) and vitamin D (800 IU) with placebo
Trial: 9673745
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg (up to 80 mg daily)
Trial: 9673745
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg (up to 40 mg daily +/− cholestyramine 4 g daily in 84% of cases)
Trial: 2589654
Drug: 2% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mepivacaine (400 mg)
Trial: 2589654
Drug: 1.5% etidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% etidocaine (300 mg)
Trial: 31837113
Drug: Lurasidone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40 or 80 mg/day)
Trial: 22085207
Drug: One-to-one communication
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-to-one communication training with direct oral feedback from the standardized patient
Trial: 17898458
Drug: 5.4 g
RxNorm normalized name: Glycerin 5.4 GM Rectal Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.4 g CLA-triacylglycerol (3.4 g as CLA) daily for 12 weeks
Trial: 17898458
Drug: 10.8 g
RxNorm normalized name: GABAPENTIN 10.8 g in 10.8 g ORAL POWDER, FOR SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 g CLA-triacylglycerol (6.8 g as CLA) daily for 12 weeks
Trial: 17898458
Drug: Placebo (10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10.8 g safflower oil) daily for 12 weeks
Trial: 17898458
Drug: 5.4 g
RxNorm normalized name: Glycerin 5.4 GM Rectal Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.4 g CLA-triacylglycerol (3.4 g as CLA)
Trial: 17898458
Drug: 10.8 g
RxNorm normalized name: GABAPENTIN 10.8 g in 10.8 g ORAL POWDER, FOR SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 g CLA-triacylglycerol (6.8 g as CLA)
Trial: 17898458
Drug: Placebo (10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10.8 g safflower oil)
Trial: 9443112
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 18 g/l of protein (F18)
Trial: 9443112
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 13 g/l of protein (F13)
Trial: 9443112
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 15 g/l of protein (F15)
Trial: 2660445
Drug: Cardiospermum ointment
RxNorm normalized name: Cardiospermum halicacabum leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiospermum ointment
Trial: 2660445
Drug: Ointment base
RxNorm normalized name: Ointment base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment base only (placebo)
Trial: 21716127
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline nasal spray
Trial: 18160462
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 microg/d for 2 years (after 1 year of treatment)
Trial: 16372331
Drug: Parenteral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral estrogen or total androgen ablation
Trial: 11994904
Drug: Metformin 2.5
RxNorm normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2.5 g/day plus rosiglitazone 2 mg bd
Trial: 11994904
Drug: Metformin 2.5
RxNorm normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2.5 g/day plus rosiglitazone 4 mg bd
Trial: 11994904
Drug: Metformin 2.5
RxNorm normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2.5 g/day plus placebo
Trial: 2179393
Drug: Cyclofenil treatment
RxNorm normalized name: cyclofenil
DrugBank: Cyclofenil (DB13472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclofenil treatment
Trial: 6153233
Drug: Anorectic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anorectic preparation ('Trimolets'; 85 mg phenylpropanolamine per capsule)
Trial: 6153233
Drug: Decongestant preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestant preparation ('Contac 500'; 50 mg phenylpropanolamine per capsule)
Trial: 26857727
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment treatment for nasal carriers of S. aureus
Trial: 23724544
Drug: gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel with 4,500 ppm F + 5% TMP (4,500 5% TMP)
Trial: 23724544
Drug: gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel with 9,000 ppm F (9,000)
Trial: 23724544
Drug: gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel with 12,300 ppm F (12,300)
Trial: 23724544
Drug: gel without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gel without F or TMP (placebo)
Trial: 23724544
Drug: gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel with 4,500 ppm F (4,500)
Trial: 18199105
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg for 4 months
Trial: 10953898
Drug: Prescription plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription plus mailed booklet
Trial: 10953898
Drug: Prescription only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription only
Trial: 9437624
Drug: Naltrexone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone plus brief drug counseling
Trial: 8499152
Drug: Primary induction
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary induction chemotherapy with a limit of 25% tumour cell mass (TCM) reduction to separate responders from non-responders
Trial: 20555312
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 25 mg equiv.
Trial: 20555312
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 50 mg equiv.
Trial: 20555312
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 100 mg equiv.
Trial: 20555312
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (all doses)
Trial: 18690985
Drug: Ceftriaxone-Vancomycin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone-Vancomycin fixed-dose combination 1.5 g B.D. for 3-10 days (Group A, n=106)
Trial: 18690985
Drug: Ceftriaxone-Vancomycin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone-Vancomycin fixed-dose combination 3.0 g B.D. for 3-10 days (Group B, n=199)
Trial: 18690985
Drug: Ceftriaxone-Vancomycin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone-Vancomycin fixed-dose combination
Trial: 12379544
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 2 x 400 mg for 4 days and topical gentamicin and polymyxin
Trial: 12379544
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and topical placebo
Trial: 12379544
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin and topical antibiotics
Trial: 8092089
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g raw potato starch (54% RS)
Trial: 8092089
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g pregelatinized starch (0% RS)
Trial: 2817915
Drug: Kenalog creams
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kenalog creams 0.025%
Trial: 2817915
Drug: Aristocort creams
RxNorm normalized name: triamcinolone acetonide Topical Cream [Aristocort]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aristocort creams 0.025%
Trial: 2817915
Drug: Aristocort ointments
RxNorm normalized name: triamcinolone acetonide Topical Cream [Aristocort]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aristocort ointments 0.1%